Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professors Irv Weissman and Ravi Majeti at Stanford University and Professor Paresh Vyas at the MRC Molecular Haematology Unit, are working on an antibody from the Stanford investigators that enables the immune system to detect and kill cancer cells.

Picture of the actin cytoskeleton stained in red.

They are now testing whether it’s safe and effective for use in people with blood cancer. In this week’s blog they tell us how they collaborated across the Atlantic to get public funding for a project that has led to a spin out with multiple backers and a promising clinical trial.

You can read more about the work on the MRC Insight blog

 

This post was originally published on MRC Insight under the title ‘Fighting cancer like an infection’ under CC BY 4.0

We want to hear about your news!

Publishing a paper? Just won an award? Get in touch with communications@rdm.ox.ac.uk

 

Similar stories

Analysis shows that funding gender equity incentives can work

Athena SWAN CVM Department General Publication Research

A paper by Oxford BRC-supported researchers says that linking research funding to Athena SWAN gender equality action plans has been associated with a rise in the number of women in mid-level leadership positions and the proportion of funding going to women.

Unexpected eating turns on liver clock genes

Department General OCDEM Publication Research

New PNAS paper finds that clock-target genes in mice livers become clock controlled only when the animals eat at unexpected times.